Browse > Article
http://dx.doi.org/10.3857/roj.2016.01697

Hypofractionated whole breast irradiation: new standard in early breast cancer after breast-conserving surgery  

Kim, Kyung Su (Department of Radiation Oncology, Seoul National University College of Medicine)
Shin, Kyung Hwan (Department of Radiation Oncology, Seoul National University College of Medicine)
Choi, Noorie (Department of Radiation Oncology, Seoul National University College of Medicine)
Lee, Sea-Won (Department of Radiation Oncology, Seoul National University College of Medicine)
Publication Information
Radiation Oncology Journal / v.34, no.2, 2016 , pp. 81-87 More about this Journal
Abstract
Hypofractionated whole breast irradiation (HF-WBI) has been proved effective and safe and even better for late or acute radiation toxicity for early breast cancer. Moreover, it improves patient convenience, quality of life and is expected to be advantageous in the medical care system by reducing overall cost. In this review, we examined key randomized trials of HF-WBI, focusing on adequate patient selection as suggested by the American Society of Therapeutic Radiology and Oncology (ASTRO) guideline and the radiobiologic aspects of HF-WBI in relation to its adoption into clinical settings. Further investigation to identify the current practice pattern or cost effectiveness is warranted under the national health insurance service system in Korea.
Keywords
Breast neoplasms; Radiotherapy; Dose hypofractionation;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Shaitelman SF, Schlembach PJ, Arzu I, et al. Acute and short-term toxic effects of conventionally fractionated vs hypofractionated whole-breast irradiation: a randomized clinical trial. JAMA Oncol 2015;1:931-41.   DOI
2 van der Laan HP, Hurkmans CW, Kuten A, Westenberg HA; EORTC-ROG Breast Working Party. Current technological clinical practice in breast radiotherapy; results of a survey in EORTC-Radiation Oncology Group affiliated institutions. Radiother Oncol 2010;94:280-5.   DOI
3 Wang EH, Mougalian SS, Soulos PR, et al. Adoption of hypofractionated whole-breast irradiation for early-stage breast cancer: a National Cancer Data Base analysis. Int J Radiat Oncol Biol Phys 2014;90:993-1000.   DOI
4 Jagsi R, Falchook AD, Hendrix LH, Curry H, Chen RC. Adoption of hypofractionated radiation therapy for breast cancer after publication of randomized trials. Int J Radiat Oncol Biol Phys 2014;90:1001-9.   DOI
5 Chapman BV, Rajagopalan MS, Heron DE, Flickinger JC, Beriwal S. Clinical pathways: a catalyst for the adoption of hypofractionation for early-stage breast cancer. Int J Radiat Oncol Biol Phys 2015;93:854-61.   DOI
6 Veronesi U, Saccozzi R, Del Vecchio M, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med 1981;305:6-11.   DOI
7 Fisher B, Bauer M, Margolese R, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 1985;312:665-73.   DOI
8 Owen JR, Ashton A, Bliss JM, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol 2006;7:467-71.   DOI
9 Fisher CM, Rabinovitch R. Frontiers in radiotherapy for earlystage invasive breast cancer. J Clin Oncol 2014;32:2894-901.   DOI
10 Yarnold J, Ashton A, Bliss J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol 2005;75:9-17.   DOI
11 Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010;362:513-20.   DOI
12 START Trialists' Group, Bentzen SM, Agrawal RK, et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 2008;9:331-41.   DOI
13 START Trialists' Group, Bentzen SM, Agrawal RK, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008;371:1098-107.   DOI
14 Haviland JS, Owen JR, Dewar JA, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 2013;14:1086-94.   DOI
15 Trans-Tasman Radiation Oncology Group. Radiation doses and fractionation schedules in non-low risk ductal carcinoma in situ (DCIS) of the breast (DCIS) [Internet]. Waratah, Australia: Trans-Tasman Radiation Oncology Group; c2016 [cited 2016 Feb 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT00470236.
16 Smith BD, Bentzen SM, Correa CR, et al. Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys 2011;81:59-68.   DOI
17 Mowery YM, Blitzblau RC. Whole-breast radiation therapy: the long and short of it. Int J Radiat Oncol Biol Phys 2014;90:990-2.   DOI
18 Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, et al. Effect of radiotherapy after breastconserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011;378:1707-16.   DOI
19 Nilsson C, Valachis A. The role of boost and hypofractionation as adjuvant radiotherapy in patients with DCIS: a metaanalysis of observational studies. Radiother Oncol 2015;114:50-5.
20 Lalani N, Paszat L, Sutradhar R, et al. Long-term outcomes of hypofractionation versus conventional radiation therapy after breast-conserving surgery for ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys 2014;90:1017-24.   DOI
21 Bane AL, Whelan TJ, Pond GR, et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Ann Oncol 2014;25:992-8.   DOI
22 Herbert C, Nichol A, Olivotto I, et al. The impact of hypofractionated whole breast radiotherapy on local relapse in patients with Grade 3 early breast cancer: a population-based cohort study. Int J Radiat Oncol Biol Phys 2012;82:2086-92.   DOI
23 Yarnold J. Hypofractionation, rationale, current status and futuredirections. In: ASTRO's 56th Annual Meeting; 2014 Sep 14-17; San Francisco, CA. Fairfax, VA: American Society for Radiation Oncology; 2014.
24 Galecki J, Hicer-Grzenkowicz J, Grudzien-Kowalska M, Michalska T, Zalucki W. Radiation-induced brachial plexopathy and hypofractionated regimens in adjuvant irradiation of patients with breast cancer: a review. Acta Oncol 2006;45:280-4.   DOI
25 Badiyan SN, Shah C, Arthur D, et al. Hypofractionated regional nodal irradiation for breast cancer: examining the data and potential for future studies. Radiother Oncol 2014;110:39-44.   DOI
26 Kim JY, Jung SY, Lee S, et al. Phase 2 trial of accelerated, hypofractionated whole-breast irradiation of 39 Gy in 13 fractions followed by a tumor bed boost sequentially delivering 9 Gy in 3 fractions in early-stage breast cancer. Int J Radiat Oncol Biol Phys 2013;87:1037-42.   DOI
27 Jagsi R, Griffith KA, Boike TP, et al. Differences in the acute toxic effects of breast radiotherapy by fractionation schedule: comparative analysis of physician-assessed and patientreported outcomes in a large multicenter cohort. JAMA Oncol 2015;1:918-30.   DOI
28 Yarnold J, Bentzen SM, Coles C, Haviland J. Hypofractionated whole-breast radiotherapy for women with early breast cancer: myths and realities. Int J Radiat Oncol Biol Phys 2011;79:1-9.   DOI
29 Appelt AL, Vogelius IR, Bentzen SM. Modern hypofractionation schedules for tangential whole breast irradiation decrease the fraction size-corrected dose to the heart. Clin Oncol (R Coll Radiol) 2013;25:147-52.   DOI
30 Tanguturi SK, Bellon JR. Hypofractionation for early-stage breast cancer: no more excuses. JAMA Oncol 2015;1:941-2.   DOI